ARS Pharmaceuticals (SPRY) EBITDA (2020 - 2026)

ARS Pharmaceuticals has reported EBITDA for 7 years, with the latest figure at -$60.1 million in Q1 2026.

• Quarterly EBITDA fell 61.78% year-over-year to -$60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.4 million (down 647.81% YoY) and the FY2025 annual result came in at -$179.4 million, down 5720.56% from the prior year.
• EBITDA slipped to -$60.1 million in Q1 2026 per SPRY's latest filing, from -$41.5 million in the prior quarter.
• Over five years, EBITDA peaked at $47.2 million in Q4 2024 and troughed at -$60.1 million in Q1 2026.
• A 5-year average of -$20.3 million and a median of -$18.0 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA plunged 224.76% in 2023, then jumped 561.54% in 2024.
• Over 5 years, EBITDA stood at -$15.4 million in 2022, then surged by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then plunged by 187.86% to -$41.5 million in 2025, then plunged by 45.05% to -$60.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$60.1 million, -$41.5 million, and -$53.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.